Erik Harris Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Erik Harris.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Erik Harris. Erik Harris is EVP & Chief Commercial Officer in Ultragenyx Pharmaceutical Inc. ($RARE).
Latest Insider Trading Transactions of Erik Harris
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 10 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Sell | S | 113.67 | 393 | 44,672 | 26,717 | 27.1 K to 26.7 K (-1.45 %) |
| May 10 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Sell | S | 113.68 | 307 | 34,900 | 27,110 | 27.4 K to 27.1 K (-1.12 %) |
| Apr 21 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Sell | S | 104.28 | 396 | 41,295 | 27,417 | 27.8 K to 27.4 K (-1.42 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Option Exercise | A | 142.47 | 11,000 | 1,567,170 | 11,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Sell | S | 138.16 | 707 | 97,679 | 27,813 | 28.5 K to 27.8 K (-2.48 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Sell | S | 138.17 | 2,470 | 341,280 | 28,520 | 31 K to 28.5 K (-7.97 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 4,636 | 0 | 30,990 | 26.4 K to 31 K (+17.59 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 5,500 | 0 | 26,354 | 20.9 K to 26.4 K (+26.37 %) |
| Feb 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Sell | S | 74.69 | 2,516 | 187,920 | 20,854 | 23.4 K to 20.9 K (-10.77 %) |
| Oct 16 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Sell | S | 88.00 | 220 | 19,360 | 23,370 | 23.6 K to 23.4 K (-0.93 %) |
| Jul 08 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Payment of Exercise | F | 86.75 | 260 | 22,555 | 23,590 | 23.9 K to 23.6 K (-1.09 %) |
| Jun 22 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Payment of Exercise | F | 78.22 | 303 | 23,701 | 23,850 | 24.2 K to 23.9 K (-1.25 %) |
| May 08 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Payment of Exercise | F | 66.26 | 209 | 13,848 | 24,153 | 24.4 K to 24.2 K (-0.86 %) |
| Apr 21 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Payment of Exercise | F | 58.57 | 210 | 12,300 | 24,362 | 24.6 K to 24.4 K (-0.85 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Option Exercise | A | 56.08 | 22,000 | 1,233,760 | 22,000 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Payment of Exercise | F | 56.08 | 824 | 46,210 | 24,572 | 25.4 K to 24.6 K (-3.24 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 3,287 | 0 | 25,396 | 22.1 K to 25.4 K (+14.87 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 7,800 | 0 | 22,109 | 14.3 K to 22.1 K (+54.51 %) |
| Oct 16 2019 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 1,208 | 0 | 14,309 | 13.1 K to 14.3 K (+9.22 %) |
| Jul 09 2019 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Payment of Exercise | F | 59.51 | 260 | 15,473 | 13,101 | 13.4 K to 13.1 K (-1.95 %) |
| Jun 21 2019 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Option Exercise | A | 63.27 | 12,000 | 759,240 | 12,000 | |
| Jun 21 2019 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 3,500 | 0 | 13,361 | 9.9 K to 13.4 K (+35.49 %) |
| Jun 21 2019 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Option Exercise | A | 63.27 | 12,000 | 759,240 | 12,000 | |
| Jun 21 2019 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 3,500 | 0 | 13,361 | 9.9 K to 13.4 K (+35.49 %) |
Page: 1